![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-desktop-headergif-63893.gif)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-mobile-headergif-78265.gif)
Active Filter(s):
Details:
Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.
Lead Product(s): Carotegrast Methyl
Therapeutic Area: Gastroenterology Product Name: AJM300
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: EA Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021